Protein engineering to design better enzyme replacement therapies for Fabry disease
This study is looking into new, improved treatments for Fabry disease, a rare inherited condition. Current treatments, called enzyme replacement therapies, can have side effects and aren't always fully effective. Researchers are using artificial intelligence to design new enzymes that they hope will work better, cause fewer immune reactions, and be needed less often. If you have Fabry disease and are over 16, you could take part by providing blood and urine samples. You might also be asked to wear a blood pressure monitor at home. While there are no direct health benefits to you, your contribution will help develop better treatments for Fabry disease in the future. The study is run by the University of Edinburgh.
At a glance
What is this study about?
Fabry disease is a rare condition that's passed down through families. It happens when certain enzymes in the body don't work properly, leading to a build-up of harmful substances in cells. This can damage many parts of the body, including the heart, kidneys, blood vessels, and nervous system, causing problems like pain, strokes, and organ damage.
Currently, some people with Fabry disease are treated with 'enzyme replacement therapy' (ERT). This involves getting regular infusions (treatment given directly into a vein). However, these treatments aren't perfect; they don't always work as well as the body's natural enzymes, can't reach all affected areas, and sometimes cause allergic reactions. These reactions can also make the treatment less effective over time. Patients often find the frequent infusions and potential side effects quite challenging.
This study is trying to find better ways to treat Fabry disease. Researchers are using clever technology, including artificial intelligence, to design new enzymes. The aim is for these new enzymes to work more effectively, have fewer side effects (especially fewer immune reactions), and potentially be given less often. The first step is to test how these new enzymes interact with patient blood samples in the lab, to see if they are less likely to trigger an immune response compared to existing treatments.
Key takeaways
- Researchers are creating new, potentially better treatments for Fabry disease.
- This study tests these new treatments in lab samples, not directly in patients.
- You can take part by providing blood and urine samples during a routine clinic visit.
- Participation helps future patients, though there are no direct benefits to you.
- The study involves minimal risk, like routine blood tests or wearing a monitor.
- It's open to people with Fabry disease over 16, not on immune-suppressing drugs or gene therapy.
Who may be eligible?
This study is looking for people who have been diagnosed with Fabry disease, either through a blood test or genetic testing. You need to be 16 years old or older to take part, and there's no upper age limit.
To make sure the study results are clear, you cannot take part if you are currently on medicines that suppress your immune system (like those used after an organ transplant), or if you've already had 'gene therapy' for Fabry disease. This is because these treatments might affect how your body responds to the new enzymes being tested.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I have a diagnosed form of Fabry disease.
- I am 16 years old or older.
- I am not taking any regular immune-suppressing medications.
- I have never received experimental gene therapy for Fabry disease.
What does participation involve?
If you decide to take part, you'll be asked to provide extra blood and urine samples. This can usually be done at the same time as your routine blood tests during a visit to your NHS clinic, making it as convenient as possible. You might also be given the option to wear a special monitor for 24 hours at home. This monitor painlessly checks your blood pressure and how your blood vessels are working. After 24 hours, you'll simply post it back to the research team. The study isn't about giving you new medication; it's focused on collecting samples to test new treatments in the laboratory.
Potential risks and benefits
Locations (1)
- University of EdinburghUnverifiedEdinburgh, Scotland
Common questions
What is Fabry disease?
Fabry disease is a rare inherited condition where certain enzymes don't work properly, causing harmful substances to build up in the body and damage organs like the heart and kidneys.
What are the new treatments being developed?
Researchers are designing new enzymes using artificial intelligence. The goal is for these new enzymes to work better and cause fewer side effects than current treatments.
Do I need to take any new medicine if I join?
No, this study does not involve taking any new medicines. It focuses on collecting blood and urine samples to test new treatments in the lab.
Will I get any money for taking part?
The information provided does not mention any payment for participation. It's a voluntary contribution to research.
How long will the study last?
The study is running from August 2024 to December 2026, but your personal involvement will likely be a single visit for samples and potentially some home monitoring.
How to find out more
Eve Miller-Hodges
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.